New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT06797635
Summary
This study is testing whether adding a new drug called patritumab deruxtecan to standard chemotherapy and immunotherapy before surgery works better for certain aggressive breast cancers. Researchers want to see if this combination helps eliminate more cancer cells before surgery compared to standard treatment alone. The trial will enroll 372 people with high-risk triple-negative or hormone receptor-low breast cancer who haven't had previous treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center ( Site 2401)
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-••••
-
Clinica Universidad de Navarra ( Site 1703)
RECRUITINGMadrid, Madrid, Comunidad de, 28027, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Reina Sofia ( Site 1702)
RECRUITINGCórdoba, 14004, Spain
Contact Phone: •••-•••-••••
-
Houston Methodist Hospital ( Site 0022)
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
-
Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
RECRUITINGBadalona, Catalonia, 08916, Spain
Contact Phone: •••-•••-••••
-
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
RECRUITINGBillings, Montana, 59102, United States
Contact Phone: •••-•••-••••
-
Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
RECRUITINGTaipei, 112, Taiwan
Contact Phone: •••-•••-••••
-
National Cheng Kung University Hospital ( Site 2503)
RECRUITINGTainan, 704, Taiwan
Contact Phone: •••-•••-••••
-
Northwest Cancer Specialists (Compass Oncology) ( Site 8003)
RECRUITINGTigard, Oregon, 97223, United States
Contact Phone: •••-•••-••••
-
Orchard Healthcare Research Inc. ( Site 0006)
RECRUITINGSkokie, Illinois, 60077, United States
Contact Phone: •••-•••-••••
-
SCRI Oncology Partners ( Site 7000)
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
Seoul National University Hospital ( Site 2400)
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 2402)
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
Taichung Veterans General Hospital ( Site 2502)
RECRUITINGTaichung, 407, Taiwan
Contact Phone: •••-•••-••••
-
Texas Oncology - DFW ( Site 8000)
RECRUITINGDallas, Texas, 75246, United States
Contact Phone: •••-•••-••••
-
UCLA Hematology/Oncology - Parkside ( Site 0021)
RECRUITINGSanta Monica, California, 90404, United States
Contact Phone: •••-•••-••••
-
Virginia Oncology Associates (VOA) ( Site 8001)
RECRUITINGNorfolk, Virginia, 23502, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.